Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are in a quiet period.
It seems to me this has always been about getting one of the companies to a liquidity event. They have made good advancements but that was always their core goal reaching a liquidity event. Until that happens or at least until they show more evidence they are close I just don’t know if anything else will move the needle. With that said I was encouraged by the comment Ken made about the potential deal on the Huntpost side of the business with what sounded like a $100 M deal with the trade show company. At this point the talk needs to turn into actions. $$$$ talks.
You’re wrong. We can agree to disagree. The CRADA work will produce the IND. Why is that so hard for you to believe.
The delay in the IND has everything to do with the CRADA timing. Do some homework.
Whatever you say champ. You are wrong on every level.
It is pretty clear that the delay in the IND was related to the CRADA approval timing. The trials that the NEI are doing through the CRADA is the very work needed to file the IND.
The government got behind on everything during COVID. It took TWO YEARS for the government to provide my parents a refund from an amended tax return for the year 2018. The reason I got every time I called on their behalf was that COVID delayed everything, people were not working and a whole host of reasons related to the virus. Two years it took to refund a simple amended return. The IND was delayed because of delays at the NEI and and NIH because they were short staffed and got behind in their work like every other governmental agency. Put your brain to work for a change instead of constantly bitching, pissing and moaning.
And Dr. Sohn is the CUBT lead on the CRADA and will be working closely with Dr. Chew, the National Eye Institute’s lead investigator on the trials. She has a vested interest in this trial’s success. And let’s not forget Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee.
I think she knows a thing or two about developing products and bringing them to market. The bears here will call her “eye candy” though which is pretty laughable. She’s fully engaged and has a lot riding on its success.
Except when it ran to .20 of course. And it is fully capable of an equally big or larger move on the right news. How many fly by nights as you describe them can say they have have entered into a Cooperative Research and Development Agreement with the NEI, to be lead to by one of if not the leading ophthalmology investigative researchers in the world, in an $11B market? Not many.
I believe he is the inventor of the IP around the Metformin eye drop solution. This is great to see.
We shall see. You just have to figure things out for yourself.
That may be good in theory but likely not reality. I don’t see too many OTC companies making sacrifices for stock holders.
Your are correct about institutional investors investing if they have something worth investing in imo. And I believe they do and is the reason I am here. They need money to progress their solutions. Financing has been a topic on this board going back a ways. I would think that if they could have obtained financing elsewhere we would have seen it by now. Maybe they are working that angle now that they have entered into a CRADA with the National Eye Institute. The long delay on any update on financing leads me to think the RS is coming. Now how and what that looks like relative to an uplisting and attracting institutional investors remains to be seen.
The sooner you learn that OTC companies could care less about retail the less rage you will have.
They need money and they are sick of dealing with the OTC crowd. They want to be uplisted to draw institutional investors that can’t buy the pinks. Why would they have informed investors without the intent to follow through?
You are wrong. I do not want to see a reverse split of the stock. But it will happen. I don’t know when bit it will happen. My preference would be at a much higher price. Are we clear champ? Stop putting words in my mouth.
They did a reverse split dude, 200:1. They had 1.4 BILlION shares prior to the RS, more than double what CUBT has now. You’re not comparing apples to apples as usual. A reverse split is coming here, whether you like it or not. Get used to the idea.
“Well it’s good” is not evidence. The other day you were criticizing someone for not having evidence to support a belief but here you are doing the same. You said insiders were selling yesterday. Where is the evidence? You make assumptions all the time without actual evidence yet criticize others for the same.
What a the evidence of that comment?
I can do math dude. You do not read responses it appears. I am not a fan of a RS split. Good day mate.
You do realize the share price goes up when there is a reverse split. Based on your posts it does not appear that you understand the concept of a reverse split. You should study up on the topic.
A RS can be a good thing if it gets you to a higher exchange where they can attract institutional investors. It also creates a very thin float, so any news can send it. They need money to advance their four solutions. What would you do?
I didn’t say it was good. I think it is inevitable. People can whine all they want. It is not going to change the course of action the company takes. Am I excited about a RS at .05. Of course not. It is not up to us retail investors however.
Dilution is adding shares to the number of shares outstanding. A RS will typically accompany a corresponding increase in price to maintain the same capitalized value pre and post split. A stock split does not dilute the ownership interests of existing shareholders.
As far as where the company is at, they are going to need money to advance their 4 drug solutions. How would you expect them to raise capital if not through some institutional investment that will include share ownership? It’s going to happen. If you do not like that prospect I would recommend selling. They need the capital to advance their business. This is very common on all exchanges.
I am basing my estimates on the company’s two year time horizon to bring drug solutions to some kind of monetization event, which is their stated business model. If I recall I believe they gained the worldwide rights to repurpose Metformin into an eye drop in February 2021. The two year time frame would be February 2023. So I backed into the dates. It seems clear to me the delay in the IND had a lot to do with the timing of securing the CRADA in addition to whatever supply issues the company had because of COVID last year.
With the CRADA announcement and Dr. Chew leading the trials, I think discussions with big pharma may begin soon. At least preliminary. AMD is such a large market and growing with an aging population. I am thinking human trials will be underway after animal studies conclude in a few months. Human trials will probably take 90 days. By the end of the year they could have a suitor interested. How long a deal takes will be contingent on the trials and terms. The CRADA agreement was a big step.
You are right. No volume and no new buyers. Hopefully the market will catch up to the news.
You are right. Dr. Chew is one of, if not the most renowned, researchers in her segment of eye care in the world. Absolute beast. For her to want to take this on speaks volumes. A Doctor of her caliber does not ask to be the Lead Investigator if for this CRADA if there is not huge potential here. By the end of 2022 big pharma will be knocking. I am willing to be as patient as needed.
Plenty? Which ones? I am really curious.
There never is any evidence about insider selling of CUBT shares. Speculation, yes, driven by conspiracy theories; evidence, none. Why would insiders be selling on news they just entered into a collaborative CRADA with the NATIONAL EYE INSTITUTE to move their Metformin eye drop solution forward. Their work just took a major step forward.
People should actually research “this cradd research thing.” LOL. Ignorance is not bliss when it comes to the CUBT CRADA.
This CRADA will get big pharma’s attention. Up to this point it has been all speculation about a relationship with the NEI. The product CUBT is collaborating on with the National Eye Institute is a Metformin eye drop solution, when the main treatment up to this point has been an actual injection in the eye. How big of a market is there for an eye drop, utilizing one of the safest and most prescribed drugs in the world (used to treat diabetes) to be repurposed to replace an injection? Large! This is a $10B industry. And now they have a formal collab. with the National Eye Institute. The market will figure it out. In the meantime good buy op. imo.
The market will wake up eventually. This is a huge step. This news creates a great buy opportunity at this price level imo. People have no idea of the process and work needed to secure a Collaborative Research and Development Agreement with the National Institute of Health’s National Eye Institute.
This is big news. The NEI is the gold standard for all things eye research. For the NEI to agree to do a CRADA with CUBT for Metformin is MASSIVE! Do your homework on this. The NEI has to believe in your product to agree to this.
And who are those people? Pretty strong g accusations. If you don’t have specifics, it is all speculation.
In May of 2021 they had the license for about three months at that time. Things take time. I am patient. They will get it done.
Or maybe not.
The company announced the grant of exclusive worldwide license from the National Institute of Health for repurposing Metformin to treat degenerative eye disease on February 4, 2021. Dr. Kapil Bharti from the National Eye Institute was added to CUBT’s Advisory Board on April 29, 2021. Dr Bharti has been involved in the development of the Metformin eye drop solution.
The company’s goal is to bring their solutions to a monetization event within a two year time frame. It has been just over one year since they were awarded the worldwide license and less than one year since Dr. Bharti joined the board. Give this management team time. They know what they are doing imo. And they are on track despite the delay in filing the IND. It is a rigorous process they are going through.
CUBT the comeback kid. What a recovery. Guess those bad loan terms were so bad after all. Most people see the potential with what the company owns. Only regret is not adding yesterday.
Indeed. Shares were stolen at great prices yesterday. People need to know what they own.
Apparently the market doesn’t care too much about the terms. The stock price is exactly where it was when I added last week. It sounds like to me you place zero value on the worldwide license CUBT has to a Metformin eye drop treatment for AMD, the initiative of which is being lead by Dr. Bharti who works at the National Eye Institute (part of the National Health Institute) and is an Advisor to CUBT management on its development. I am thinking more people are more intrigued by this potential than the terms of a short term loan to fund their research which is needed to advance to the product stage eventually.